Publications in collaboration with researchers from KU Leuven (30)

2026

  1. Characteristics, management, and outcomes of patients with VIPoma–A retrospective analysis of the ENETS database

    Journal of Neuroendocrinology, Vol. 38, Núm. 7

  2. European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids

    Journal of Neuroendocrinology, Vol. 38, Núm. 4

2025

  1. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 405, Núm. 10476, pp. 383-395

  2. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

    ESMO Open, Vol. 10, Núm. 3

  3. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 43, Núm. 35, pp. 3714-3727

2024

  1. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.

    Journal of Clinical Oncology, Vol. 42, pp. 3503-3503

  2. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

    Journal of Clinical Oncology, Vol. 42, Núm. 3_suppl, pp. LBA768-LBA768

  3. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer

    New England Journal of Medicine, Vol. 391, Núm. 21, pp. 2014-2026

  4. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.

    Journal of Clinical Oncology, Vol. 42, Núm. 3_suppl, pp. 116-116

2023

  1. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  2. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194

2022

  1. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms

    European Journal of Cancer, Vol. 168, pp. 80-90

2021

  1. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 665-677

  2. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

    Annals of Oncology, Vol. 32, Núm. 5, pp. 600-608

2020

  1. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

    Annals of Oncology, Vol. 31, Núm. 1, pp. 88-95

  2. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer

    New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218

2019

  1. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

    Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131

  2. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

    Oncologist, Vol. 24, Núm. 2, pp. 185-192

2018

  1. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

    Annals of Oncology, Vol. 29, Núm. 3, pp. 602-609

  2. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: Exploratory analyses of the RAISE trial and validation in an electronic medical record data set

    ESMO Open, Vol. 3, Núm. 3